Korea launches safety watch on meningitis vaccine MenQuadfi
NCT ID NCT07621653
First seen Jun 05, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study will monitor the safety of the MenQuadfi vaccine in 706 people aged 6 weeks to 55 years in South Korea. Researchers will track side effects like injection-site reactions and serious adverse events as the vaccine is used in real-world clinics. The goal is to confirm the vaccine's safety profile outside of controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL IMMUNIZATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MenQuadfi (meningococcal groups A, C, Y, W polysaccharide tetanus toxoid conjugate vaccine)
What this could lead to
If successful, this study will confirm that MenQuadfi is safe for routine use in Korea, helping protect against serious meningococcal disease.
What could go wrong
This is an observational safety study, not a test of effectiveness. It may not detect rare side effects due to its size and real-world setting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.